News & Updates

Osimertinib extends progression-free survival (PFS) sevenfold longer than placebo in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) following definitive chemoradiotherapy, as shown in the primary analysis of the phase III LAURA study presented at ASCO 2024. This breakthrough makes osimertinib the first EGFR inhibitor to show benefit in a stage III setting.

Several older adults who undergo emergency laparotomy (EL) in Singapore are frail, and these patients have a longer length of stay in the intensive care unit (ICU) and a higher rate of 90-day mortality than nonfrail counterparts, a study has found.

Patients undergoing a shorter-than-recommended fasting period prior to coronary angiography have significantly higher satisfaction scores, according to a study. This finding highlights the feasibility of revised fasting protocols.

An intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake and meal replacement diet (5:2 MR) helps keep a lid on blood sugar and promote weight loss in adults with overweight or obesity and early type 2 diabetes (T2D), according to the results of the open-label EARLY* study from China.

Body size appears to have an impact on the prognostic outcomes in patients with cancer, reveals a study. Both hand grip strength (HGS) and subcutaneous fat affect the influence BMI has on such prognosis.